Status:
COMPLETED
A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Hepatitis C, Chronic
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
This 6-arm study will assess the efficacy and safety of RO5024048 (R7128) in combination with the approved doses of Pegasys (180micrograms sc weekly) + Copegus (1000/1200mg po daily) (SOC), versus SOC...
Eligibility Criteria
Inclusion
- Adult patients, 18-65 years of age
- Chronic hepatitis C, genotype 1 or 4
- Treatment-naive
Exclusion
- No previous treatment with any interferon- or ribavirin-based therapy
- Other forms of liver disease
- HIV infection
Key Trial Info
Start Date :
February 1 2001
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2012
Estimated Enrollment :
413 Patients enrolled
Trial Details
Trial ID
NCT00869661
Start Date
February 1 2001
End Date
February 1 2012
Last Update
November 2 2016
Active Locations (66)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States, 35294
2
La Jolla, California, United States, 92037-1030
3
Sacramento, California, United States, 95817
4
San Diego, California, United States, 92103-8465